Journal article icon

Journal article

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

Abstract:

AIMS/HYPOTHESIS: The aim of the study was to examine the 48 month outcome of treating recent-onset type 1 diabetic patients for 6 days with humanised CD3-antibody, ChAglyCD3. METHODS: Eighty patients, aged 12-39 years, were recruited for a phase 2 multicentre trial and randomised to placebo (n=40) or ChAglyCD3 (n=40) treatment by a third party member; participants and care-givers were blinded. The change in insulin dose (U kg(-1)day(-1)) over 48 months was chosen as primary endpoint and compa...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1007/s00125-009-1644-9

Authors


Expand authors...
Journal:
Diabetologia
Volume:
53
Issue:
4
Pages:
614-623
Publication date:
2010-04-05
DOI:
EISSN:
1432-0428
ISSN:
0012-186X
URN:
uuid:94e17191-c0b8-4e2c-82be-0717d29fc23b
Source identifiers:
51975
Local pid:
pubs:51975

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP